RxDoctor Payments Data

Sarah Harmon, PA

Physician Assistant · Glen Dale, WVNPI 1881304525

Payments from drug & device makers

$1,209in general payments, 2019–2025

Across 45 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$423
  • GSK$204
  • Sobi, Inc$100
  • Daiichi Sankyo Inc.$99
  • Novocure Inc.$96
  • Amgen$85
  • plus $203 from 8 others

What the payments were for

  • Food & beverage$1,01084%
  • Education$19916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,209 in reported general payments places this provider in the 75th percentile of 833 physician assistant providers in West Virginia.

See all physician assistant providers in West Virginia

Medicare billing

Part B allowed, 2024
$6,928
Medicare patients
82
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$80,489
Breztri AerosphereBudesonide/Glycopyr/Formoterol74$48,350
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$19,225
Spiriva RespimatTiotropium Bromide24$12,060
Breo ElliptaFluticasone/Vilanterol16$10,547
SymbicortBudesonide/Formoterol Fumarate36$10,264
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$10,060
Arnuity ElliptaFluticasone Furoate26$7,200
Albuterol Sulfate HfaAlbuterol Sulfate169$5,902
BreynaBudesonide/Formoterol Fumarate19$3,843
Roflumilast40$3,501
Ventolin HfaAlbuterol Sulfate40$2,496
Hydroxyurea23$415
Montelukast Sodium21$290
Acyclovir16$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$204$108,296159 claims
AstraZenecaBreztri Aerosphere, Symbicort$423$58,613110 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$17$31,28557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 833 physician assistant providers in West Virginia.

Other physician assistant in Glen Dale

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →